The global esophageal cancer drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). Esophageal cancer drugs are commonly used to treat adenocarcinoma, squamous cell carcinoma, and other kinds of esophageal cancer. Men are more likely than women to be diagnosed with esophageal cancer. The majority of cases of esophageal cancer are seen in low-income countries. Malawi, Mongolia, Kenya, and Bangladesh, had the highest risk of esophageal cancer, according to a World Cancer Research Fund (WCRF) International report from 2018. Esophageal cancer can be treated with chemo, immunotherapy, and targeted medication therapies. Some medications, such as the XELIRI combination of Capecitabine and Irinotecan Hydrochloride, are used in combination and have been approved by the Food and Drug Administration (FDA).

Increased research and development, as well as the introduction of novel products by key players, are projected to propel the global esophageal cancer drugs market forward during the forecast period. The global market for esophageal cancer drugs is predicted to rise rapidly due to increased research and development for new drug discovery for the treatment of esophageal cancer. For instance, researchers at Case Western Reserve University in the US discovered in February 2019 that blocking two molecular pathways that communicate signals inside cancer cells can diminish esophageal adenocarcinoma (EAC), the most frequent esophageal malignancy in the US. These data point to JNK/TGF-beta-targeted therapy as a novel esophageal cancer drugs option. 

Furthermore, age, gender, tobacco, alcohol, Barrett's oesophagus, obesity, and achalasia are all substantial risk factors for esophageal cancer. During the forecast period, these factors are projected to boost demand for the global esophageal cancer drugs market. Achalasia patients, had a 50-fold higher risk of esophageal squamous cell carcinoma than the general population. Achalasia affects 9 to 10 persons in every 100,000 people around the globe.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Esophageal Cancer Drugs Market by Segment

By Therapy Type  

• Chemotherapy 

o Docetaxel

o Irinotecan

o Trifluridine and Tipiracil

o Carboplatin and Paclitaxel

o Cisplatin and 5-fluorouracil

o Cisplatin with Capecitabine

By Distribution Channel 

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy 

Global Esophageal Cancer Drugs Market by Region